Skip to main content

Advertisement

SpringerLink
Log in

Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB)

  • Female Urology (L Cox, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Overactive bladder syndrome (OAB) negatively affects the quality of life of patients and their interactions with society. Treatment of OAB starts with behavioral modification and then pharmacotherapy using monotherapy with either antimuscarinics or β3 agonists. The third-line more invasive approaches are the next treatment option currently recommended. Both antimuscarinic agents and β3 agonists work through a different molecular pathway. This brings up the potential of having an additive effect when using a combination treatment for patients with OAB. Currently, the potential for using combination therapy to treat OAB in patients who had no improvement with a monotherapy approach before we attempt a more invasive approach is being explored. Several studies have shown the benefits of combination therapy which will be an additional option to the tools to treat OAB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Abrams P, Blaivas JG, Stanton SL, Andersen JT. The standardisation of terminology of lower urinary tract function. The International Continence Society Committee on Standardisation of Terminology. Scand J Urol Nephrol Suppl. 1988;114:5–19.

    CAS  PubMed  Google Scholar 

  2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78. https://doi.org/10.1002/nau.10052.

    Article  PubMed  Google Scholar 

  3. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(6 Suppl 1):2–6.

    Article  Google Scholar 

  4. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132–8. https://doi.org/10.1111/j.1464-410X.2010.09993.x.

    Article  PubMed  Google Scholar 

  5. Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Comorbidities and personal burden of urgency urinary incontinence: a systematic review. Int J Clin Pract. 2013;67(10):1015–33. https://doi.org/10.1111/ijcp.12164.

    Article  CAS  PubMed  Google Scholar 

  6. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388–95. https://doi.org/10.1111/j.1464-410X.2008.07601.x.

    Article  PubMed  Google Scholar 

  7. Chiarelli PE, Mackenzie LA, Osmotherly PG. Urinary incontinence is associated with an increase in falls: a systematic review. Aust J Physiother. 2009;55(2):89–95. https://doi.org/10.1016/S0004-9514(09)70038-8.

    Article  PubMed  Google Scholar 

  8. Noguchi N, Chan L, Cumming RG, Blyth FM, Naganathan V. A systematic review of the association between lower urinary tract symptoms and falls, injuries, and fractures in community-dwelling older men. Aging Male. 2016;19(3):168–74. https://doi.org/10.3109/13685538.2016.1169399.

    Article  PubMed  Google Scholar 

  9. • Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological A, Society of Urodynamics FPM. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80. Disucss guideline of diagnosis and treatment of OAB. https://doi.org/10.1016/j.juro.2015.01.087.

    Article  PubMed  Google Scholar 

  10. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–62. https://doi.org/10.1016/j.eururo.2008.06.047.

    Article  CAS  PubMed  Google Scholar 

  11. Andersson KE. New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxin A. Ther Clin Risk Manag. 2013;9:161–70. https://doi.org/10.2147/TCRM.S33052.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Apostolidis A, Averbeck MA, Sahai A, Rahnama’i MS, Anding R, Robinson D, et al. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015). Neurourol Urodyn. 2017;36(4):882–93. https://doi.org/10.1002/nau.23170.

    Article  PubMed  Google Scholar 

  13. Wang CC, Jiang YH, Kuo HC. Efficacy and adherence of flexibly adding on a second antimuscarinic agent for patients with refractory overactive bladder. Low Urin Tract Symptoms. 2017;9(1):27–32. https://doi.org/10.1111/luts.12103.

    Article  CAS  PubMed  Google Scholar 

  14. Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65(4):755–65. https://doi.org/10.1016/j.eururo.2013.11.010.

    Article  CAS  PubMed  Google Scholar 

  15. Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J. 2015;9(9–10):343–50.

    Article  Google Scholar 

  16. Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72(3):389–99. https://doi.org/10.1016/j.eururo.2017.01.037.

    Article  CAS  PubMed  Google Scholar 

  17. Staskin D, Herschorn S, Fialkov J, Tu LM, Walsh T, Schermer CR. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study). Int Urogynecol J. 2018;29(2):273–83. https://doi.org/10.1007/s00192-017-3377-5.

    Article  PubMed  Google Scholar 

  18. Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballea S, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324–33. https://doi.org/10.1016/j.eururo.2018.03.020.

    Article  CAS  PubMed  Google Scholar 

  19. Banakhar MA, Al-Shaiji TF, Hassouna MM. Pathophysiology of overactive bladder. Int Urogynecol J. 2012;23(8):975–82. https://doi.org/10.1007/s00192-012-1682-6.

    Article  PubMed  Google Scholar 

  20. Michel MC, Chapple CR. Basic mechanisms of urgency: preclinical and clinical evidence. Eur Urol. 2009;56(2):298–307. https://doi.org/10.1016/j.eururo.2009.05.028.

    Article  PubMed  Google Scholar 

  21. Drake MJ, Kanai A, Bijos DA, Ikeda Y, Zabbarova I, Vahabi B, et al. The potential role of unregulated autonomous bladder micromotions in urinary storage and voiding dysfunction; overactive bladder and detrusor underactivity. BJU Int. 2017;119(1):22–9. https://doi.org/10.1111/bju.13598.

    Article  PubMed  Google Scholar 

  22. Birder LA. Nervous network for lower urinary tract function. Int J Urol. 2013;20(1):4–12. https://doi.org/10.1111/j.1442-2042.2012.03210.x.

    Article  PubMed  Google Scholar 

  23. Chapple C. Pathophysiology of the lower urinary tract and CNS. Can Urol Assoc J. 2011;5(5 Suppl 2):S126–7.

    Article  Google Scholar 

  24. Haga N, Aikawa K, Shishido K, Takahashi N, Yanagida T, Yamaguchi O. Effect of long-term oxybutynin administration on c-Fos expression in spinal neurons: inhibition of antimuscarinics on bladder afferents in conscious rats. Urology. 2009;73(1):200–4. https://doi.org/10.1016/j.urology.2008.04.038.

    Article  PubMed  Google Scholar 

  25. Yamaguchi O. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action. Int J Urol. 2013;20(1):28–39. https://doi.org/10.1111/iju.12008.

    Article  CAS  PubMed  Google Scholar 

  26. Yokoyama O, Yusup A, Miwa Y, Oyama N, Aoki Y, Akino H. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol. 2005;174(5):2032–6. https://doi.org/10.1097/01.ju.0000176793.50410.9e.

    Article  CAS  PubMed  Google Scholar 

  27. Cardozo L, Hessdorfer E, Milani R, Arano P, Dewilde L, Slack M, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int. 2008;102(9):1120–7. https://doi.org/10.1111/j.1464-410X.2008.07939.x.

    Article  CAS  PubMed  Google Scholar 

  28. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int. 2004;93(1):71–7. https://doi.org/10.1111/j.1464-410X.2004.04561.x.

    Article  CAS  PubMed  Google Scholar 

  29. Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract. 2006;60(8):959–66. https://doi.org/10.1111/j.1742-1241.2006.01067.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93(3):303–10. https://doi.org/10.1111/j.1464-410X.2004.04606.x.

    Article  CAS  PubMed  Google Scholar 

  31. Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, et al. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. BJU Int. 2013;112(3):373–85. https://doi.org/10.1111/bju.12174.

    Article  CAS  PubMed  Google Scholar 

  32. Gotoh M, Yokoyama O, Nishizawa O, Japanese Propiverine Study G. Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial. Int J Urol. 2011;18(5):365–73. https://doi.org/10.1111/j.1442-2042.2011.02732.x.

    Article  CAS  PubMed  Google Scholar 

  33. Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010;105(1):58–66. https://doi.org/10.1111/j.1464-410X.2009.09086.x.

    Article  CAS  PubMed  Google Scholar 

  34. Kaplan SA, Cardozo L, Herschorn S, Grenabo L, Carlsson M, Arumi D, et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. Int J Clin Pract. 2014;68(9):1065–73. https://doi.org/10.1111/ijcp.12464.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Yamaguchi O, Uchida E, Higo N, Minami H, Kobayashi S, Sato H, et al. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. Int J Urol. 2014;21(6):586–93. https://doi.org/10.1111/iju.12372.

    Article  CAS  PubMed  Google Scholar 

  36. Coelho A, Antunes-Lopes T, Gillespie J, Cruz F. Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: an immunohistochemical study. Neurourol Urodyn. 2017;36(8):1972–80. https://doi.org/10.1002/nau.23224.

    Article  CAS  PubMed  Google Scholar 

  37. Limberg BJ, Andersson KE, Aura Kullmann F, Burmer G, de Groat WC, Rosenbaum JS. Beta-adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. Cell Tissue Res. 2010;342(2):295–306. https://doi.org/10.1007/s00441-010-1053-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Otsuka A, Shinbo H, Hasebe K, Matsumoto R, Ozono S. Effects of a novel beta(3)-adrenoceptor agonist, AJ-9677, on relaxation of the detrusor muscle: an in vitro study. Int J Urol. 2008;15(12):1072–6. https://doi.org/10.1111/j.1442-2042.2008.02165.x.

    Article  CAS  PubMed  Google Scholar 

  39. Rouget C, Rekik M, Camparo P, Botto H, Rischmann P, Lluel P, et al. Modulation of nerve-evoked contractions by beta3-adrenoceptor agonism in human and rat isolated urinary bladder. Pharmacol Res. 2014;80:14–20. https://doi.org/10.1016/j.phrs.2013.12.006.

    Article  CAS  PubMed  Google Scholar 

  40. G DA, Maria Condino A, Calvi P. Involvement of beta3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: Direct evidence by [(3)H]-acetylcholine release experiments in the isolated detrusor. Eur J Pharmacol. 2015;758:115–22.

    Article  Google Scholar 

  41. • Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. International Journal of Clinical Practice. 2013;67(7):619–32. This is an analysis of radomised,double-blind pacebo controlled on efficacy and safety of mirabegron in treatment of OAB. https://doi.org/10.1111/ijcp.12194.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. • Batista JE, Kolbl H, Herschorn S, Rechberger T, Cambronero J, Halaska M, et al. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther Adv Urol. 2015;7(4):167–79. https://doi.org/10.1177/1756287215589250. This is an important phase III trial comparing mirabegron efficacy and safety with solifenacin.

    Article  CAS  Google Scholar 

  43. Sebastianelli A, Russo GI, Kaplan SA, McVary KT, Moncada I, Gravas S, et al. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: comparison with placebo and tolterodine. Int J Urol. 2018;25(3):196–205. https://doi.org/10.1111/iju.13498.

    Article  CAS  PubMed  Google Scholar 

  44. Chapple CR, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele JJ, Bosman B, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24(9):1447–58. https://doi.org/10.1007/s00192-013-2042-x.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305. https://doi.org/10.1016/j.eururo.2012.10.048.

    Article  CAS  PubMed  Google Scholar 

  46. •• Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67(3):577–88. This an important study about using combination treatment of slifenacin and mirabegron for treatment of OAB. https://doi.org/10.1016/j.eururo.2014.02.012.

    Article  CAS  PubMed  Google Scholar 

  47. •• Abrams P, Kelleher C, Staskin D, Kay R, Martan A, Mincik I, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, phase II study (SYMPHONY). World J Urol. 2017;35(5):827–38. Symphony trial showing efficacy and safety of combination therapy mirabegron and solifenacin.

    Article  Google Scholar 

  48. Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week Solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol. 2016;70(1):136–45. https://doi.org/10.1016/j.eururo.2016.02.030.

    Article  CAS  PubMed  Google Scholar 

  49. •• Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120(4):562–75. https://doi.org/10.1111/bju.13882. Synergy trial: comparing efficacy and safety of combination therapy mirabegron and solifenacin versus monotherapy or placebo.

    Article  CAS  Google Scholar 

  50. Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, et al. Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU Int. 2015;116(4):612–22. https://doi.org/10.1111/bju.13068.

    Article  CAS  PubMed  Google Scholar 

  51. Drake MJ, MacDiarmid S, Al-Shukri S, Barkin J, Fianu-Jonasson A, Herschorn S, et al. Adding mirabegron to solifenacin to treat overactive bladder has little impact on postvoid residual volume or urinary retention risk. Urology. 2017;104:1–4. https://doi.org/10.1016/j.urology.2017.03.004.

    Article  PubMed  Google Scholar 

  52. Shin JH, Kim A, Choo MS. Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy. Investig Clin Urol. 2017;58(4):261–6. https://doi.org/10.4111/icu.2017.58.4.261.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care. 2000;6(11 Suppl):S565–73.

    CAS  PubMed  Google Scholar 

  54. Natalin R, Lorenzetti F, Dambros M. Management of OAB in those over age 65. Curr Urol Rep. 2013;14(5):379–85. https://doi.org/10.1007/s11934-013-0338-5.

    Article  PubMed  Google Scholar 

  55. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7. https://doi.org/10.1001/jamainternmed.2014.7663.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016;7(5):204–16. https://doi.org/10.1177/2042098616659412.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Fox C, Smith T, Maidment I, Chan WY, Bua N, Myint PK, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43(5):604–15. https://doi.org/10.1093/ageing/afu096.

    Article  PubMed  Google Scholar 

  58. Gibson W, MacDiarmid S, Huang M, Siddiqui E, Stolzel M, Choudhury N, et al. Treating overactive bladder in older patients with a combination of mirabegron and solifenacin: a Prespecified analysis from the BESIDE study. Eur Urol Focus. 2017;3(6):629–38. https://doi.org/10.1016/j.euf.2017.08.008.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Toledo, 3000 Arlington Ave, Toledo, OH, 43614, USA

    Ahmed El-Zawahry

Authors
  1. Ahmed El-Zawahry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmed El-Zawahry.

Ethics declarations

Conflict of Interest

Ahmed El-Zawahry each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Female Urology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El-Zawahry, A. Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB). Curr Urol Rep 20, 33 (2019). https://doi.org/10.1007/s11934-019-0893-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-019-0893-5

Keywords

Search

Navigation